
2023-04
喜讯 | 博生吉医药TAA06注射液顺利完成I期临床试验的首例患者回输
中国苏州,2023年4月17日——博生吉医药科技,一家以突破性细胞新药研发为主要业务的国家高新技术企业,今日公告,公司自主研...
PersonGen BioTherapeutics (Suzhou) Co., Ltd.
PersonGen BioTherapeutics (Suzhou) Co. Ltd is a biotech company focusing on developing leading-edge cellular therapeutics. The company is committed to developing CAR-related therapeutic and analytical antibodies, novel CAR- products, and allogeneic cellular therapies. The company has developed a comprehensive pipeline of products and a world-leading allogeneic off-the-shelf UCAR-Vδ1 T-cell R&D platform.
PersonGen.Anke Cellular Therapeutics Co., Ltd.
PersonGen-Anke Cellular Therapeutics Co., Ltd. is a subsidiary company and the manufacturing base of PersonGen BioTherapeutics. The company is equipped with the global-leading fully-automated, closed manufacturing system for cellular therapeutics. It also has the most advanced facilities for the manufacturing of clinical-grade DNA plasmids and lentiviruses. The company has developed fully validated manufacturing processes of CAR-T, allogeneic γδT and UCAR-γδT products.
Read More
PersonGen BioTherapeutics is one of the first company in China focusing on the development of CAR-T and other cellular immunotherapies.
We are driven by our values “Care for People, Cure Every Patient”, and is committed to being the world leader on developing allogeneic cellular therapies against tumors and autoimmunity diseases.
中国苏州,2023年4月17日——博生吉医药科技,一家以突破性细胞新药研发为主要业务的国家高新技术企业,今日公告,公司自主研...
近日,第十届“科创江苏”创新创业大赛生命科学领域决赛在南京圆满收官,博生吉医药科技(苏州)有限公司凭借在细胞治疗领域的突破性技术成果与产业化...
2025年9月17日,中国合肥 —— 国内领先的细胞治疗企业博生吉安科细胞技术有限公司宣布,其自主研发的全球创新型靶向CD7自体CAR-T细...
9月4日,备受业界瞩目的第十届“创客中国”江苏省中小企业创新创业大赛总决赛在南京圆满落幕。在这场顶级赛事中,博生吉医药科技(苏州)有限公司凭...
Conceptual Pilot Study, Patient Recruitment
Read More